A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 06 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 08 Dec 2016 Planned End Date changed from 1 Oct 2020 to 1 Sep 2017.